Vytrus Biotech, S.A. (FRA:V5P)

Market Cap	94.05M +391.1%
Revenue (ttm)	8.09M +54.4%
Net Income	1.95M +180.2%
EPS	n/a
Shares Out	n/a
PE Ratio	48.18
Forward PE	35.11
Dividend	n/a
Ex-Dividend Date	n/a

Volume	111
Average Volume	33
Open	14.00
Previous Close	14.00
Day's Range	14.00 - 14.00
52-Week Range	2.32 - 14.00
Beta	n/a
RSI	76.87
Earnings Date	Mar 26, 2026

About Vytrus Biotech

Vytrus Biotech, S.A. develops, produces, and sells active ingredients from plant stem cells in Spain and internationally. The company offers Clarivine that activates skin’s regeneration processes; Quora Noni biomics for rejuvenating the skin microbiota; Deobiome Noni, a prebiotic deodorant to reduce the generation of body odour; Sarcoslim Re-Shape, an active ingredient to reduce fat on tissue; Capilia Longa that improves density in hair, eyebrows, and eyelashes; and Luminia Granatum that brightens skin, whitens dark spots, evens skin tone, and ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2009
• Employees: 37
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: V5P

Financial Performance

In 2024, Vytrus Biotech's revenue was 6.09 million, an increase of 29.51% compared to the previous year's 4.70 million. Earnings were 1.02 million, an increase of 87.36%.